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Secreted phospholipases A2 (sPLA2s) are extracellular enzymes that catalyze the release 
of free fatty acids and lysophospholipids from membrane phospholipids and also bind to 
different receptors (e.g., PLA2R1 or integrins). To date, 12 mammalian sPLA2s have been 
identified, which play a critical role in pathophysiological processes including inflammation 
and cancer. sPLA2s activate immune cells such as human neutrophils (PMNs) by enzy-
matic activity- or receptor-mediated mechanisms. In addition, human PMNs synthesize 
and store human group V (hGV) and human group X (hGX) sPLA2s in their granules, but 
only the former is released upon cellular activation. We investigated the effects of sPLA2s 
on the release of proangiogenic and antiangiogenic factors by PMNs. We found that 
exogenous hGV and hGX sPLA2s induce the release of vascular endothelial growth fac-
tor (VEGF)-A, angiopoietin 1 (Ang1), and CXCL8/IL-8. Only hGV induces the secretion of 
the antiangiogenic isoform of VEGF-A, namely, VEGF-A165b. While the release of VEGF-A, 
Ang1, and CXCL8/IL-8 was likely mediated by hGV enzymatic activity and/or binding 
to PLA2R1 and heparan sulfate proteoglycans, the release of VEGF-A165b requires the 
interaction with αVβ3 and α4β1 integrins. We also provide evidence that endogenous hGV 
released by N-formyl-met-leu-phe (fMLF)-activated PMNs is involved in the release of 
angiogenic factors. The translational relevance of these data is supported by our findings 
that hGV expression is increased in human samples of lung cancer which are infiltrated 
by PMNs. Overall, our results suggest that the hGV–neutrophil axis may play a relevant 
role in the modulation of cancer-related inflammation and angiogenesis.
Keywords: secreted phospholipase a2, neutrophil, vascular endothelial growth factor, angiopoietin, lung tumor, 
integrin, Pla2r1
inTrODUcTiOn
Secreted phospholipases A2 (sPLA2s) are extracellular enzymes that catalyze the hydrolysis of the 
sn − 2 position of membrane glycerophospholipids to release free fatty acids and lysophospholipids, 
thereby regulating several processes including the production of lipid mediators (1). However, 
sPLA2 effects are not related only to their enzymatic activity but also to their ability to activate target 
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cells through the engagement of different targets [e.g., PLA2R1, 
heparan sulfate proteoglycans (HSPGs), integrins] (2–9). To date, 
12 mammalian sPLA2s, namely, groups IB, IIA, IIC, IID, IIE, 
IIF, III, V, X, XIIA, XIIB, and otoconin-95, have been identified 
(5, 10). They often play critical roles in pathophysiological pro-
cesses, including inflammation and cancer (1, 5, 11, 12). Indeed, 
sPLA2s are expressed in inflamed tissues and tumors (1, 12–15). In 
addition, several immune cells are both sources and/or targets of 
sPLA2s (16–21). In particular, sPLA2s activate human neutrophils 
(PMNs) inducing elastase and CXCL8/IL-8 release and activating 
ERK1/2 and p38 MAP kinases by a receptor-mediated mecha-
nism (8, 21–23). In addition, PMNs store human group V (hGV) 
and human group X (hGX) in their granules (16, 19), but only the 
former is released in response to the bacterial N-formylmethionyl 
peptide, formyl-methionyl-leucylphenylalanine (fMLF) (16, 19).
PMNs are innate immune cells with primary roles in the acute 
phase of inflammation and resistance against invading patho-
gens (24). Because of their terminally differentiated phenotype 
and short half-life, the role of PMNs in tumor development has 
been considered marginal. Recent evidence changed this point 
of view. Indeed, tumor-associated neutrophils (TAN) can exert 
anti-tumoral as well as pro-tumoral functions and findings 
derived from murine models suggest that PMNs display unsus-
pected plasticity (25, 26). Epidemiological studies indicate an 
association between TAN and clinical outcome in several but not 
all tumors (27–33). In early stages of lung tumors, PMNs exert 
immunostimulatory properties but acquire immunosuppressive 
features as the disease progresses (34, 35). There is some evidence 
that PMNs can modulate tumor initiation and growth through the 
production of angiogenic factors (36), but further investigations 
are required to better understand the role of PMNs in modulating 
tumor angiogenesis.
Angiogenesis, the formation of new blood vessels, and 
lymphangiogenesis, the formation of new lymphatic vessels, are 
complex processes that require the coordinated action of several 
factors, namely, vascular endothelial growth factors (VEGFs) and 
angiopoietins [angiopoietin 1 (Ang1) and Ang2] (37, 38). Several 
proangiogenic and antiangiogenic factors have been identified. 
VEGF-A and VEGF-B are key mitogens for endothelial cells 
and can act both as pro- and antiangiogenic factors due to the 
different spliced forms (39–41). For instance, the splicing variant 
VEGF-A165 exists in two different isoforms: VEGF-A165a is the 
most potent proangiogenic variant, whereas VEGF-A165b is an 
antiangiogenic isoform (42–44). Endothelial cell maturation is 
also promoted by the angiopoietins (Ang1 and Ang2), whose 
role can be either proangiogenic or antiangiogenic depending on 
the microenvironment (45, 46). The key regulators of lymphangi-
ogenesis are VEGF-C and VEGF-D (38, 47).
Immune cells are important sources as well as targets of 
proangiogenic and antiangiogenic factors (48). In particular, 
PMNs release a variety of proangiogenic and antiangiogenic 
factors and play important roles in several models of inflamma-
tory and tumor angiogenesis (36, 49–51). Indeed, PMNs release 
VEGF-A in response to fMLF, LPS, and phorbolmyristate acetate 
(PMA), while Ang1 is secreted only in response to PMA (50). 
It is unknown whether sPLA2s can modulate the production of 
proangiogenic and antiangiogenic factors from PMNs.
Since we demonstrated that sPLA2s induce the production of 
angiogenic factors from human macrophages (17), in this study, 
we sought to investigate the production of pro- and antiangio-
genic factors by PMNs in response to different forms of sPLA2s.
MaTerials anD MeThODs
reagents
The following were purchased: l-glutamine, antibiotic– 
antimycotic solution (10,000  IU/ml penicillin, 10  mg/ml 
streptomycin, and 25  µg/ml amphotericin B), Triton X-100, 
Histopaque®-1077, bovin serum albumin (BSA), Heparinase I 
and III Blend from Flavobacterium heparinum, N-formyl-met-
leu-phe (fMLF), phenolphthalein β-d-glucuronide sodium salt, 
detoxified LPS (from E. coli serotype 0111:B4), PMA, brefeldin A, 
and cycloheximide (Sigma-Aldrich, St. Louis, MO, USA); RPMI 
and fetal calf serum (FCS, endotoxin level <0.1  EU/ml) (MP 
Biomedicals Europe, Illkirch, France); P11, TCS 2314 (Tocris 
Bioscience, UK); anti-human VEGF-A165 (monoclonal mouse 
IgG2B; Clone 26603) and anti-human VEGF165b (monoclonal 
mouse IgG1; Clone 56-1) (R&D System, Minneapolis, MN, 
USA). Target-specific primers for VEGFA165a, VEGFA165b, VEGFB, 
VEGFC, VEGFD, Ang1, Ang2, and β-actin were produced and 
purified by Custom Primers (Life Technologies, Milan, Italy). 
The recombinant sPLA2s human group IB, hGIIA, hGIIE, hGIIF, 
hGV, hGX, and hGXIIA and the inhibitors Me-Indoxam and 
RO092906A were prepared in the laboratory of Gerard Lambeau 
and were a generous gift from and Michael H. Gelb (Departments 
of Chemistry and Biochemistry, University of Washington, Seattle, 
WA, USA). sPLA2 preparations were routinely checked for LPS 
contamination (Limulus amebocyte Test, MP Biomedicals) and 
discarded if the LPS concentration was above the detection limit 
of the assay (0.125 EU/ml). All other reagents were from Carlo 
Erba (Milan, Italy).
isolation and Purification of human 
neutrophils
Granulocytes were isolated from buffy coats of healthy 
donors obtained from the Leukapheresis Unit. After dextran 
sedimentation, PMNs were obtained by centrifugation over 
Histopaque®-1077 at 400 × g for 30 min, at 22°C, at a 1:1 ratio. 
Finally, PMNs were isolated by negatively removing all con-
taminating cells using the MACSxpress Neutrophil Isolation Kit 
and MACSxpress Erythrocyte Depletion Kit (Miltenyi Biotec, 
Bologna, Italy). This procedure yields a population of CD66b+ 
cells with a purity greater than 99% as assessed by flow cytometry. 
PMNs were suspended (5 × 106 cells/ml) in complete medium 
(RPMI 1640 containing 5% FCS, 2  mM l-glutamine, and 1% 
antibiotic–antimycotic solution) and incubated in different plates 
(Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) at 37°C in 
a humidified atmosphere of 5% CO2 and 95% air. After 30 min of 
rest, the cells were used for the experiments.
cell incubations
PMNs were incubated (37°C, 5  min–3  h) in RPMI 1640 con-
taining 5% FCS, 2  mM l-glutamine, and 1% antibiotic–anti-
TaBle 1 | Primer sequences and conditions for quantitative Pcr.
Target Product length (bp) Ta (°c) Primer (5′–3′) genBank accession no. or reference
VEGFA165a 79 60 Forward: GCCTTGCCTTGCTGCTCTAC NM_003376
Reverse: TGATTCTGCCCTCCTCCTTCTG
VEGFA165b 157 60 Forward: GAGCAAGACAAGAAAATCCC (43)
Reverse: GTGAGAGATCTGCAAGTACG
VEGFB 128 60 Forward: AGGACAGAGTTGGAAGAGGAG NM-003377
Reverse: AGGAAGAGCCAGTTGTAAGATG
VEGFC 197 60 Forward: ATGTTTTCCTCGGATGCTGGA NM_005429
Reverse: CATTGGCTGGGGAAGAGTTT
VEGFD 226 60 Forward: GTATGGACTCTCGCTCAGCAT NM_004469
Reverse: AGGCTCTCTTCATTGCAACAG
Ang1 73 60 Forward: CAGGAGGATGGTGGTTTGATG NM_001314051
Reverse: TGGTTTTGTCCCGCAGTATAGAA
Ang2 65 60 Forward: TTCCTCCTGCCAGAGATGGA NM_001118888
Reverse: TGCACAGCATTGGACACGTA
β-Actin 99 60 Forward: TGCGTGACATTAAGGAGAAG NM_001101
Reverse: GCTCGTAGCTCTTCTCCA
Ta, annealing temperature.
3
Loffredo et al. Activation of PMN by sPLA2
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 443
mycotic solution and stimulated with various concentrations 
(0.3–10 µg/ml) of human GIB, GIIA, GIIE, GIIF, GIII, GV, GX, 
GXIIA, fMLF (50  nM), detoxified LPS (100  ng/ml), and PMA 
(80 nM). In selected experiments, hGV and hGX (3 µg/ml) were 
preincubated (37°C, 20  min) with increasing concentrations 
(0.01–10 µM) of their inhibitors Me-Indoxam or RO092906A. In 
other experiments, PMNs were preincubated (37°C, 1 h) with hepa-
rinase (0.4 U/ml) or (37°C, 30 min) with P11 (100 nM) and/or TCS 
2314 (100 nM), brefeldin A (10 µg/ml), cycloheximide (10 µg/ml) 
and then stimulated (37°C, 30  min) with hGV (3  µg/ml). In 
selected experiments, PMNs were preincubated (37°C, 15 min) 
with Me-Indoxam or RO092906A and then stimulated with fMLF 
(37°C, 10 min). At the end of the experiment, the supernatants 
were removed, centrifuged (1,000 × g, 4°C, 5 min) and stored at 
−80°C for subsequent determination of mediator release.
rT-Pcr
Total cellular RNA was isolated from PMNs using the SV RNA iso-
lation system (Promega, Madison, WI, USA), treated with RNase-
free DNase I and resuspended in DEPC water. RNA concentration 
and quality were assessed by spectrophotometry. Total mRNA was 
reverse-transcribed (Superscript III Reverse Transcriptase 200 U, 
Life Technologies) and quantitative PCR (qPCR) was carried 
out in iCycler-iQ5 real-time PCR detection system (Bio-Rad, 
Hercules, CA, USA) using SYBR Green Master Mix (Bio-Rad). 
Target-specific primers for VEGF165a, VEGFA165b, VEGFB, VEGFC, 
VEGFD, Ang1, Ang2, and β-actin suitable for qPCR were produced 
and purified by Custom Primers (Life Technologies, Milan, Italy) 
and are reported in Table 1. β-Actin was used as housekeeping 
gene to normalize cycle threshold (Ct) values using the 2−ΔCt 
formula. The data were analyzed with iCycler iQ analysis software 
(Bio-Rad).
Mediator release assays
The concentration of VEGF-A, VEGFA165b, VEGF-B, VEGF-C, 
VEGF-D, Ang1, Ang2, and CXCL8/IL-8 in the supernatants, lysed 
or freshly isolated PMNs (lysed in Tryton 0.1%) was measured 
in duplicate determinations using commercially available ELISA 
kits (R&D System). The ELISA sensitivity is 31.1–2,000  pg/ml 
for VEGF-A, 31.1–4,000  pg/ml for VEGF-A165b, 9.4–300  pg/ml 
for VEGF-B, 62–4,000 pg/ml for VEGF-C, 31.1–2,000 pg/ml for 
VEGF-D, 156.25–10,000 pg/ml for Ang1, 31.1–4,000 pg/ml for 
Ang2, and 31.1–2,000 pg/ml for CXCL8/IL-8. β-Glucuronidase 
release was measured with a colorimetric assay.
Pla2 activity assay
A modified liposomal-based fluorescent assay was used to 
measure PLA2 activity in neutrophil supernatants. Briefly, a 
PLA2 substrate cocktail consisting of 7-hydroxycoumarinyl- 
arachidonate (0.3  mM), 7-hydroxycoumarinyl-linolenate 
(0.3 mM), hydroxycoumarinyl-6 heptenoate (0.3 mM), 10 mM 
dioleoylphosphatidylcholine (DOPC), and 10 mM dioleoylphos-
phatidylglycerol (DOPG) was prepared in ethanol. Liposomes 
were formed by gradually adding 77 µl substrate/lipid cocktail to 
10 ml PLA2 buffer (50 mM Tris–HCl at pH 8.9, 100 mM NaCl, 
1 mM CaCl2) while stirring rapidly over 1 min using a magnetic 
stirrer (Invitrogen EnzChek® phospholipase A2 assay). Neutrophil 
supernatants (50 µl) was added to 96-well plates, and PLA2 activ-
ity was initiated by adding 50 µl substrate cocktail. Fluorescence 
(excitation at 360 nm and emission at 460 nm) was measured, 
and specific activity (relative fluorescent units/μg protein/min) 
for each sample was calculated.
immunohistochemistry analysis of  
non-Tumor and Tumor lung Tissues for 
hgV and cD66b
Non-tumor and tumor lung tissues were obtained from patients 
affected by lung adenocarcinoma (HCV−, HBsAg−, and HIV-1−) 
undergoing lung resection. Immunohistochemical staining has 
been carried out on 4-µm lung cancer serial sections from 
formalin-fixed, paraffin-embedded tissues, in order to evalu-
ate the expression of hGV and CD66b. Negative control slides 
without primary antibody were included for each staining (not 
shown). Paraffin slides were deparaffinized in xylene and rehy-
drated through graded alcohols. Antigen retrieval was performed 
with slides heated in 1 mM EDTA buffer (pH 9.0) for hGV and 
0.01 M citrate buffer (pH 6.0) for CD66b, in a bath for 20 min 
at 97°C. After antigen retrieval, the slides were allowed to cool 
FigUre 2 | human secreted phospholipases a2 (sPla2s) induce the release of vascular endothelial growth factors (VegFs), ang1, and cXcl8/il-8 
from PMns. PMNs were incubated (37°C, 3 h) with sPLA2 [5 µg/ml, human group IB (hGIB), hGIIA, hGIIE, hGIIF, hGV, hGX, and hGXIIA] or control medium (a–D). 
At the end of incubation, the supernatants were collected and centrifuged (1,000 × g, 4°C, 5 min). VEGF-A (a), CXCL8/IL-8 (B), Ang1 (c), and VEGF-A165b (D) were 
determined by ELISA. The values are expressed as picograms or nanograms of mediators per 106 cells. The results are the mean ± SD of eight different 
preparations of PMNs. *p < 0.05 vs. control.
FigUre 1 | human neutrophils (PMns) constitutively express different forms of vascular endothelial growth factors (VegF) and angiopoietins. (a) 
VEGFA165a, VEGFA165b, VEGFB, VEGFC, VEGFD, Ang1, and Ang2 mRNA expression in PMNs. The results are the mean ± SD of four different preparations of PMNs. 
RNA extraction from resting PMNs and RT-PCR was performed as described under Section “Materials and Methods.” (B) Detection of VEGF and Ang proteins. 
Freshly isolated PMNs were lysed in Tryton 0.1%, and the concentrations of VEGFs and Angs were determined by ELISA. The results are the mean ± SD of six 
different preparations of PMNs.
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and rinsed with TBS. The endogenous peroxidase activity was 
inactivated with 3% hydrogen peroxide. Following the protein 
block (BSA 5% in PBS 1×), the slides were incubated with a 
polyclonal rabbit antibody against hGV (NBP2-31558, Novus 
Biologicals, Littleton, CO, USA, dilution 1:100) or a monoclonal 
mouse anti-human CD66b antibody (555723, BD Pharmingen, 
San Jose, CA, USA, dilution 1:400 at 4°C overnight). The sections 
were rinsed in TBS and incubated with biotinylated anti-rabbit or 
anti-mouse antibodies, respectively, for 1 h at room temperature. 
Immunoreactivity was visualized using 3,3′-diaminobenzidine 
(DAB) and avidin–biotin–peroxidase complex. Finally, sections 
were weakly counterstained with hematoxylin, mounted, and 
interpreted using light microscope.
statistical analysis
The data are expressed as mean values ±SD of the indicated num-
ber of experiments. Statistical analysis was performed with Prism 
6 (GraphPad Software) by one-way analysis of variance followed 
by Dunnett’s test (when comparison was made against a control) 
or Bonferroni’s test (when comparison was made between each 
pair of groups). Statistically significant differences were accepted 
when the p value was at least ≤0.05.
resUlTs
sPla2s induce the release of 
Proangiogenic and antiangiogenic  
Factors by PMns
To evaluate the impact of sPLA2 on the production of angiogenic 
and lymphangiogenic factors by human PMNs, we first assessed 
the basal expression of VEGFs and Angs. Freshly isolated PMNs 
constitutively expressed VEGF-A, VEGF-B, and Ang1 at both 
mRNA and protein levels. By contrast, no expression of VEGF-C 
and VEGF-D (lymphangiogenic factors) and Ang2 could be 
detected (Figures  1A,B). Interestingly, PMNs constitutively 
expressed VEGF-A165b (Figures 1A,B), the antiangiogenic splice 
variant of VEGF-A165 (42).
We then evaluated the effects of several human recombinant 
sPLA2s on the secretion of VEGF-A, VEGF-A165b, VEGF-B, and 
Ang1 as well as the proangiogenic chemokine CXCL8/IL-8 from 
PMNs. Several sPLA2s induced the release of VEGF-A (Figure 2A) 
and CXCL8/IL-8 (Figure 2B) and promoted the release of Ang1 
(Figure 2C). However, at the concentration used (5 µg/ml), the 
release of VEGFA and CXCL8 was significant upon stimulation 
with hGV and hGX, and the release of Ang1 was significant 
FigUre 3 | effect of increasing concentrations of human group V (hgV) and human group X (hgX) on vascular endothelial growth factor (VegF)-a 
(a), cXcl8/il-8 (B), angiopoietin 1 (ang1) (c), and VegF-a165b (D) release from PMns. PMNs were incubated (37°C, 3 h) with hGV and hGX (0.3–10 µg/ml) 
or control medium. (e–h) Kinetics of hGV-induced release of VEGFs, Ang1, and CXCL8/IL-8 from PMNs. The cells were incubated (37°C, 5–30 min) with hGV  
(3 µg/ml). At the end of incubations, the supernatants were collected and centrifuged (1,000 × g, 4°C, 5 min). Data are the mean ± SD of different eight preparations 
of PMNs *(for hGV) and §(for hGX) p < 0.05 vs. control.
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upon stimulation with hGIIF, hGV, and hGX. These results 
were paralleled by the highest β-glucuronidase release used as 
a marker of exocytosis (Figure S1A in Supplementary Material) 
suggesting the release of preformed mediators rather than de novo 
synthesis. By contrast, no secretion of VEGF-B (Figure S1B in 
Supplementary Material) could be observed in any of the tested 
conditions. Interestingly, hGV and, to a lesser extent, hGIIA were 
the only sPLA2s to induce the secretion VEGF-A165b (Figure 2D).
To better understand the mechanisms of sPLA2 neutrophil 
stimulation, we performed dose–response and time-dependent 
experiments with hGV and hGX sPLA2s, which are more effective 
in stimulating human PMNs and are the only sPLA2s expressed 
by these cells (16). Figure 3 shows that the release of VEGF-A 
(Figure 3A), CXCL8/IL-8 (Figure 3B), and Ang1 (Figure 3C) in 
response to hGV and hGX was induced by concentrations as low 
as 1 µg/ml. By contrast, Figure 3D shows that VEGF-A165b secre-
tion was observed only with hGV, but not with hGX, at all tested 
concentrations. Moreover, hGV induced the release of these 
mediators as early as after 5 min of stimulation (Figures 3E,H).
To verify whether hGV-induced secretion of proangiogenic 
and antiangiogenic mediators requires de novo protein synthesis, 
neutrophils were stimulated with hGV in the presence or absence 
of brefeldin A (an inhibitor of anterograde cellular transport and 
protein secretion) or cycloheximide (an inhibitor of protein syn-
thesis). Neither brefeldin A nor cycloheximide affected the spon-
taneous release of VEGF-A, CXCL8/IL-8, Ang1, and VEGF-A165b 
(data not shown). However, brefeldin A but not cycloheximide sig-
nificantly inhibited the release of these mediators induced by hGV 
(Table S1 in Supplementary Material). Moreover, we measured 
VEGF-A, Ang1, and VEGF-A165b protein levels in supernatants 
and cellular lysates of unstimulated and hGV-stimulated PMNs 
and found that total protein levels (supernatants plus cellular 
lysates) of angiogenic mediators were not significantly modulated 
by hGV stimulation (Table S2 in Supplementary Material).
To corroborate these findings and to exclude a non-specific 
PMN activation by sPLA2, we assessed the secretion of VEGF-A, 
VEGF-A165b, Ang1, and CXCL8/IL-8 following the stimulation of 
PMNs with well-known neutrophil stimuli, such as fMLF, PMA, 
and LPS. Even though all these stimuli induced the release of 
VEGF-A (Figure 4A) and CXCL8/IL-8 (Figure 4B), the secre-
tion of Ang1 (Figure 4C) was only induced by PMA. By contrast, 
none of the tested stimuli induced the release of VEGF-A165b 
(Figure 4D). Taken together, these results indicate that hGV was 
the only sPLA2 able to induce the release of preformed pro- and 
antiangiogenic molecules, whereas the effect of hGX was limited 
to proangiogenic factors.
hgV-induced secretion of angiogenic  
and antiangiogenic Factors requires  
the interaction with Different Targets
Several evidences demonstrate that PMNs express PLA2R1 that 
is involved in sPLA2-induced neutrophil activation (8, 21–23). 
To verify whether hGV enzymatic activity and/or PLA2R1 were 
involved in the production of pro- and antiangiogenic fac-
tors induced by hGV, we stimulated PMNs in the presence of 
Me-Indoxam. This inhibitor protrudes out of the catalytic groove 
when bound to sPLA2s, thereby leading to steric hindrance and 
hence interfering with the sPLA2–receptor interaction (52). We 
have previously shown that Me-Indoxam prevents receptor-medi-
ated activation of HLMs and PMNs stimulated with sPLA2s (17, 
18, 21, 53). hGV also binds HSPGs that mediate its internalization 
FigUre 5 | (a–D) Effect of Me-Indoxam or with Heparinase on human group V (hGV)-induced vascular endothelial growth factor (VEGF)-A, CXCL8/IL-8, Ang1, and 
VEGF-A165b release from PMNs. hGV (3 µg/ml) was preincubated (37°C, 20 min) with Me-Indoxam (0.1 µM) or control medium. PMNs were then incubated (37°C, 
1 h) with heparinase (0.4 U/ml) or control medium and then stimulated (37°C, 30 min) with hGV alone or with the combination of hGV with Me-Indoxam. (e,F) αVβ3 
(P11) and α4β1 (TCS2314) receptor antagonists inhibit GV-induced PMNs production of antiangiogenic factors. PMNs were preincubated (37°C, 30 min) with or 
without P11 and TCS 2314 (100 nM) and then stimulated (37°C, 30 min) with hGV (3 µg/ml). Data are the mean ± SD of eight different preparations of PMNs. 
*p < 0.05 vs. respective control. §p < 0.05 vs. hGV alone.
FigUre 4 | effect of fMlF, lPs, and phorbolmyristate acetate (PMa) on vascular endothelial growth factors (VegFs), angiopoietin 1 (ang1), and 
cXcl8/il-8 release from PMns. PMNs were incubated (37°C, 3 h) with fMLF (50 nM), LPS (100 ng/ml), PMA (80 nM), or control medium (a–D). At the end of 
incubation, the supernatants were collected and centrifuged (1,000 × g, 4°C, 5 min). VEGF-A (a), CXCL8/IL-8 (B), Ang1 (c), and VEGF-A165b (D) were determined 
by ELISA. The values are expressed as picograms or nanograms of mediators per 106 cells. The results are the mean ± SD of eight different preparations of PMNs. 
*p < 0.05 vs. control.
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(8). To verify a possible role for HSPGs, PMNs were pre-treated 
with heparinase to eliminate surface HSPGs before stimulation 
with hGV. Both Me-indoxam and heparinase pre-treatment 
markedly reduced the secretion of VEGF-A (Figure 5A), CXCL8/
IL-8 (Figure 5B), and Ang1 (Figure 5C). Surprisingly, the release 
of VEGF-A165b (Figure 5D) was not inhibited, instead it was sig-
nificantly increased by Me-Indoxam and to a lesser extent also by 
heparinase pre-treatment. To explain these findings, we reasoned 
that Me-Indoxam and heparinase pre-treatment could enhance 
hGV binding to a different cell surface target on PMNs.
Two independent studies have shown that sPLA2s can activate 
human monocytes by binding to αVβ3 and α4β1 integrins (3, 7), 
which are also expressed on PMNs (54, 55). hGIIA is structur-
ally related to hGV (8, 56) and binds to αVβ3 and α4β1 integrins 
through a specific domain, different from the catalytic center or 
the PLA2R1-binding site (3, 7). To investigate whether integrins 
could be involved in hGV-mediated release of VEGF-A165b, we 
stimulated PMNs with hGV in the presence of the two integrin 
antagonists P11 and TCS 2314, which inhibit αVβ3 and α4β1, 
respectively (57, 58). The combination of these inhibitors mark-
edly reduced the release of VEGF-A165b (Figure 5E). The specificity 
of this finding is supported by the observation that the secretion 
of CXCL8/IL-8 was not affected (Figure 5F).
endogenous sPla2s Modulate  
fMlF-induced neutrophil activation  
in an autocrine Fashion
fMLF induces the release of hGV by human PMNs (16, 19). We 
confirmed these results, showing an increased sPLA2 activity in 
FigUre 6 | effect of Me-indoxam (a,B) and rO092906a (c,D) on fMlF-induced vascular endothelial growth factor (VegF)-a and cXcl8/il-8 release 
from PMns. Cells were preincubated (37°C, 20 min) with or without Me-Indoxam and RO092906A (0.1 µM) and then stimulated (37°C, 1–6 h,) with fMLF (50 nM). 
VEGF-A (a–c) and CXCL8/IL-8 (B–D) release was determined by ELISA. Data are the mean ± SD of eight different preparations of PMNs. *p < 0.05 vs. fMLF alone.
FigUre 7 | lung cancer express human group V (hgV) and neutrophils (cD66b+ cells). Sections of non-tumor (a–D) and tumor lung tissues (e–h) were 
stained for hGV [(c,D,g,h); brown] or CD66b [(a,B,e,F); brown]. Panels (B,D,F,h) display higher magnification (20×) of panels (a,c,e,g) (10×), respectively.
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supernatants from fMLF-stimulated PMNs which was inhibited by 
Me-Indoxam but not by the hGX-specific inhibitor RO092906A 
(Figure S2 in Supplementary Material) (59). Since we found that hGV 
induces VEGF-A, CXCL8/IL-8, Ang1, and VEGF-A165b (Figure 3) 
release, it would be conceivable that also fMLF induced the release 
of these mediators in an hGV-dependent manner. However, in our 
model, fMLF only promoted the secretion of VEGF-A and CXCL8/
IL-8 (Figure  4). Figure  3 shows that the concentration of hGV 
required for the release of VEGF-A (Figure 3A) and CXCL8/IL-8 
(Figure 3B) was 0.3 µg/ml whereas that for the release of Ang1 
(Figure  3C) and VEGF-A165b (Figure  3D) was at least 1  µg/ml. 
Therefore, we measured the enzymatic activity of several concen-
trations of recombinant hGV and found that the sPLA2 activity 
in supernatants from fMLF-stimulated PMNs corresponded to a 
concentration of recombinant hGV ≤0.3 µg/ml (data not shown). 
Thus, it is likely that the release of hGV in response to fMLF is 
in our conditions insufficient to induce VEGF-A165b and Ang1 
release. Nevertheless, we asked whether fMLF-induced secretion 
of VEGF-A and CXCL8/IL-8 was mediated by the release of endog-
enous hGV. To address this question, PMNs were stimulated with 
fMLF in the presence or absence of Me-Indoxam or RO092906A. 
As expected, Me-indoxam reduced VEGF-A (Figure  6A) and 
CXCL8/IL-8 (Figure 6B) secretion while RO092906A had no effect 
(Figures 6C,D), suggesting an involvement of hGV but not hGX in 
fMLF-mediated neutrophil activation.
expression of hgV and neutrophils  
in lung cancers
Our results show that hGV induces the release of proangiogenic 
and antiangiogenic factors by PMNs. Since angiogenesis is a hall-
mark of cancer-related inflammation (60) and PMNs infiltrate 
several human tumors (61), we assessed the expression of hGV 
and CD66b+ neutrophils by immunohistochemistry in neoplastic 
lung tissue samples. Figure 7 shows that hGV (Figures 7G,H) 
and CD66b (Figures 7E,F) were expressed in lung cancer sam-
ples but not in non-tumor areas (Figures  7A–D, respectively). 
These data suggest that hGV, expressed in lung adenocarcinoma 
microenvironment, can modulate tumor angiogenesis through 
the activation of TAN.
DiscUssiOn
This study demonstrates that human PMNs constitutively express 
and contain several proangiogenic (VEGF-A165, VEGF-B, and 
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Ang1) and antiangiogenic (VEGF-A165b) factors. Interestingly, 
human PMNs, similar to other circulating immune cells (e.g., 
basophils) (62), do not express lymphangiogenic factors (VEGF-C 
and VEGF-D). We observed that several human recombinant 
sPLA2s can selectively induce the release of pro- and antiangio-
genic factors from PMNs. In particular, hGV and hGX, which are 
the most effective sPLA2s in activating human PMNs, stimulate 
the secretion of VEGF-A, Ang1, and CXCL8/IL-8, while hGV 
is unique in inducing VEGF-A165b secretion. Critically and in 
contrast with VEGF-A, Ang1, and CXCL8/IL-8, the binding of 
hGV to integrins appears to be required for VEGF-A165b secretion. 
Indeed, the effect of hGV on VEGF-A165b secretion was abrogated 
by the addition of known inhibitors of αVβ3 and α4β1 integrins, 
suggesting that hGV physically interacts with these integrins. 
Endogenous hGV is released by fMLF-stimulated human neu-
trophils and acts in an autocrine/paracrine fashion to modulate 
VEGF-A and CXCL8/IL-8 release. The translational relevance of 
these findings is supported by the increased expression of hGV 
in neutrophil-infiltrated lung cancer samples compared to non-
tumor lung tissue.
On the one hand, neutrophils are modulators of inflammatory 
and tumor angiogenesis (36, 51). On the other hand, sPLA2s have 
been implicated in cancer (13, 15). In this study, we sought to 
investigate whether sPLA2s induce PMN secretion of angiogenic 
factors. Strikingly, we found a remarkable heterogeneity in the 
response to sPLA2s. hGV and hGX induced the highest levels of 
VEGF-A, Ang1, and CXCL8/IL-8. hGV and, to a lesser extent, 
hGIIA are the only tested sPLA2s to promote the secretion of the 
antiangiogenic factor VEGF-A165b. This molecule arises from an 
alternative splicing at the exon 8 distal site of VEGF-A mRNA and 
binds to both VEGFR-1 and VEGFR-2 (but not to co-receptor 
neuropilin-1) (42). However, VEGF-A165b fails to induce VEGFR-2 
tyrosine phosphorylation and to activate the downstream signal-
ing pathway that characterizes the proangiogenic isoform VEGF-
A165a (42–44). As such, VEGF-A165b restrains tumor growth and 
impairs angiogenesis in systemic sclerosis and peripheral artery 
disease (63–66). Our results support a model in which human 
neutrophil stimulation with hGV induces a mixed secretion 
profile whose functional outcome likely depends on the balance 
between proangiogenic and antiangiogenic factors. Further 
in vitro (e.g., endothelial cell tube formation assays) and ex vivo 
(e.g., immunohistochemistry analysis of neutrophil infiltration, 
hGV expression, and vascular patter in tumor biopsies) studies 
are required to define the role of hGV-induced neutrophil release 
of proangiogenic and antiangiogenic factors in inflammatory and 
tumor angiogenesis.
Human group V, an sPLA2 expressed by PMNs, induces 
VEGF-A, Ang1, and VEGF-A165b secretion as early as 5  min 
after stimulation and independently of de novo protein synthe-
sis. Indeed, freshly isolated PMNs contain these mediators as 
assessed in protein lysates. These results suggest that pro- and 
antiangiogenic factors are preformed and rapidly released upon 
activation. We also found that hGV stimulation does not increase 
VEGF-A, Ang1, and VEGF-A165b mRNA levels (data not shown), 
indicating that hGV preferentially acts by modulating the release 
of these factors rather than by acting at the level of transcription 
or alternative splicing. The signals responsible for the constitutive 
expression of angiogenic mediators, in particular VEGF-A165b, in 
PMNs are not known. VEGF-A is stored almost exclusively in 
the specific (β) granules (49), by contrast, Ang1 is predominantly 
located in the cytosolic fraction (50). Further studies are needed 
to understand the molecular details of VEGF-A165b expression in 
resting and hGV-stimulated PMNs.
We also demonstrate that the hGV enzymatic activity and/or 
its binding to PLA2R1 as well as HSPGs are required for VEGF-A, 
Ang1, and CXCL8/IL-8 but not for VEGF-A165b release that con-
versely requires the interaction of hGV with the integrins αVβ3 
and α4β1. The hGV-activated signaling pathways downstream of 
integrins required for VEGF-A165b release have yet to be defined. 
fMLF induces the release of endogenous hGV that modulate the 
secretion of VEGF-A and CXCL8/IL-8 but not of VEGF-A165b, 
likely because of the low level of endogenous hGV, insufficient 
to drive VEGF-A165b secretion. Nevertheless, we cannot exclude 
that in  situations of high density of PMNs (e.g., in the context 
of acute inflammation), the concentrations of hGV may reach 
the minimum required to stimulate VEGF-A165b release, possibly 
driving a switch toward antiangiogenic properties of PMNs.
To evaluate the in vivo relevance of our findings, we assessed the 
expression of hGV and CD66b (a marker of neutrophils) in human 
lung cancer and found a higher expression of hGV in neutrophil-
infiltrated tumor lung tissue compared to non-tumor lung samples. 
These results suggest that PMNs may be activated by hGV in the 
context of lung cancer. Whether this interaction results in the 
release of proangiogenic and/or antiangiogenic factors has still 
to be determined. Since VEGF-A165b restrains tumor growth and 
progression in several experimental models, our results support 
the exploration of the hGV–neutrophil axis in human lung cancer.
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